Search

Your search keyword '"Tonini, Gian Paolo"' showing total 574 results

Search Constraints

Start Over You searched for: Author "Tonini, Gian Paolo" Remove constraint Author: "Tonini, Gian Paolo"
574 results on '"Tonini, Gian Paolo"'

Search Results

7. Neuroblastoma (Peripheral neuroblastic tumours)

8. List of Contributors

10. Data from Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors

11. Data from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

12. Supplementary Table 1 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

13. Supplementary Table 2 from Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors

14. Supplementary Table 1 from Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors

15. Supplementary Figure S4 from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

16. Supplementary Materials and Methods from A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

20. Supplementary Table 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

21. Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

22. Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

23. Supplementary Table 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

24. Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

25. Supplementary Figure 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

29. Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

30. Supplementary Data 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

31. Supplementary Figure Legend from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

32. Data from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients

33. Supplementary Methods from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

34. Supplementary Table 3 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

35. Supplementary Figure 1 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

36. Supplementary Figure 2 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

37. Supplementary Figure 4 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

38. Supplementary Table 1 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

39. Supplementary Table 2 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

40. Supplementary Figure 3 from Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma

41. Supplementary Methods, Figures 1-4, Tables 1-3 from Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients

47. The p53 Codon 72 Pro/Pro Genotype Identifies Poor-Prognosis Neuroblastoma Patients: Correlation with Reduced Apoptosis and Enhanced Senescence by the p53-72P Isoform

49. Loss of 10q26.1–q26.3 in association with 7q34–q36.3 gain or 17q24.3–q25.3 gain predict poor outcome in pediatric medulloblastoma

Catalog

Books, media, physical & digital resources